A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs.
Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most common adverse events.
The combination of everolimus plus panobinostat did not appear to produce promising outcomes in metastatic RCC patients.
Read more in Investigational New Drugs here